<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="148">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00002777</nctid>
  <trial_identification>
    <studytitle>Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer</studytitle>
    <scientifictitle>RANDOMIZED PHASE II STUDY IN FIRST LINE HORMONAL TREATMENT FOR METASTATIC BREAST CANCER WITH EXEMESTANE OR TAMOXIFEN IN POSTMENOPAUSAL PATIENTS</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EORTC-10951</secondaryid>
    <secondaryid>EORTC-10951</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - exemestane
Treatment: drugs - tamoxifen citrate

Treatment: drugs: exemestane


Treatment: drugs: tamoxifen citrate


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven adenocarcinoma of the breast that is metastatic
             and progressive or locally recurrent and inoperable

          -  At least one bidimensionally measurable or evaluable lesion

               -  Lytic bone lesions on x-ray/CT scan, surrounded by calcified bone, and at least 1
                  cm

               -  Bidimensionally measurable extraosseous disease required for patients on
                  bisphosphonates

               -  The following are not considered evaluable:

                    -  Previously irradiated lesions

                    -  Lymphangitic spread

                    -  Ascites

                    -  Blastic bone lesions

                    -  Pleural effusions

          -  No rapidly progressive disease for which hormonal therapy is not indicated

          -  No massive visceral disease (i.e., more than one third of any organ)

          -  No brain metastases

          -  Hormone receptor status:

               -  Estrogen receptor positive or progesterone receptor positive, defined by 1 of the
                  following:

                    -  At least 10 femtomoles H3-estrogen or at least 20 femtomoles

                    -  H3 progesterone binding per mg of cytosol protein by DCC or sucrose density
                       method

                    -  At least 0.10 femtomoles H3-estrogen or at least 0.20 femtomoles

                    -  H3-progesterone binding per mg of DNA by IF/EIA technique

                    -  Positive immunohistochemistry noted on pathology report

               -  Unknown receptor status eligible provided:

                    -  Disease-free interval of at least 2 years since adjuvant therapy or initial
                       surgery (if no adjuvant therapy), including most recently treated tumor in
                       bilateral breast cancer if status unknown in one primary tumor

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Sex:

          -  Female

        Menopausal status:

          -  Postmenopausal by 1 of the following:

               -  Natural menopause and more than 1 year since last menstrual period (LMP)

               -  Radiation-induced oophorectomy and more than 1 year since LMP

               -  Chemotherapy induced menopause if:

                    -  At least 1 year since LMP (+ 1 year post-tamoxifen)

                    -  Serum FSH and LH and plasma estradiol levels in postmenopausal range

                    -  LHRH-induced amenorrhea

               -  Surgical castration

                    -  Patients under age 56 with prior hysterectomy and 1 or both ovaries intact
                       or tamoxifen-induced amenorrhea with at least 12 months since prior
                       tamoxifen must have postmenopausal serum FSH and LH and plasma estradiol
                       concentrations

        Performance status:

          -  ECOG (WHO) 0-2

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.5 times upper limit of normal (ULN)

          -  SGOT/SGPT less than 2.5 times ULN (less than 5 times ULN with liver metastases)

        Renal:

          -  Creatinine less than 1.5 times ULN

        Cardiovascular:

          -  No deep venous thrombosis

        Other:

          -  No mental incapacitation

          -  No severe concurrent disease

          -  No prior or concurrent malignancy except curatively treated carcinoma in situ of the
             cervix or basal cell or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent immunotherapy

        Chemotherapy:

          -  See Disease Characteristics

          -  At least 3 weeks since chemotherapy for metastatic disease and recovered

          -  No more than 1 prior chemotherapy regimen for metastatic disease

          -  Prior adjuvant chemotherapy allowed if disease free for at least 6 months

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  No prior hormonal therapy for advanced disease (e.g., tamoxifen or LHRH agonists)

          -  Prior adjuvant tamoxifen allowed if disease free for at least 6 months

          -  No other concurrent hormonal therapy, including steroids

        Radiotherapy:

          -  Recovered from toxic effects of prior radiotherapy

          -  Concurrent palliative radiotherapy, including whole brain irradiation, allowed

        Surgery:

          -  See Disease Characteristics

          -  No prior ovariectomy for advanced disease

        Other:

          -  No other concurrent investigational drugs

          -  Concurrent bisphosphonates allowed if short term (7 days) for hypercalcemia due to
             suspect tumor flare or if on prior bisphosphonates with bidimensionally measurable
             extraosseous lesion</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/1996</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>342</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Austin Hospital - Heidelberg</hospital>
    <hospital>Bankstown - Lidcombe Hospital - Bankstown</hospital>
    <postcode>2170 - Liverpool</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>NSW 2200 - Bankstown</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels (Bruxelles)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Haine Saint Paul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>La Louviere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Namur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Wilrijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Cloud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>'s-Gravenhage (Den Haag, The Hague)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amersfont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leidschendam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Maastricht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Purmerend</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Roermond</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Sittard</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Tilburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Veldhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Cebu City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Ljubljana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>European Organisation for Research and Treatment of Cancer - EORTC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
      exemestane or tamoxifen may fight cancer by blocking the uptake of estrogen.

      PURPOSE: Randomized phase II/III trial to compare the effectiveness of exemestane with that
      of tamoxifen in treating postmenopausal women who have locally recurrent or metastatic breast
      cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00002777</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Paridaens, MD, PhD</name>
      <address>University Hospital, Gasthuisberg</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>